Blood tests and BRAF for thyroid nodules
Part of Blood & lymphatic, Cancer, Hormones & metabolism clinical trials.
This trial studies whether routine blood counts and a BRAF genetic test can help predict cancer in thyroid nodules that were found to be suspicious (Bethesda 3 category) before surgery. The goal is to better understand which nodules are cancerous.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a thyroid nodule that was reported as Bethesda 3 (suspicious) on a fine-needle aspiration biopsy.
- You have decided to have surgery to remove your thyroid (thyroidectomy).
- You have had standard blood tests done (complete blood count) before surgery.
- You agree to allow your tissue and blood sample to be tested for BRAF gene changes and used anonymously in research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether it is safe to simply monitor (watch closely) a small thyroid nodule that has a certain biopsy result (Bethesda IV) instead of removing it right away. You would not receive a treatment, but would have regular checkups and ultrasounds to see if the nodule changes.
This study looks at how doctors talk with patients who have a thyroid nodule that may need a biopsy. It aims to improve communication and help patients feel more involved in their care.
This study looks at ways to better estimate the cancer risk of thyroid nodules that are “unclear” on standard testing. It uses information from your clinical history, ultrasound findings, and additional lab/genetic-type features to help sort which nodules are more likely to be cancer.
This trial is for people with certain types of thyroid nodules that are considered low risk. Instead of surgery right away, the study will follow the nodules over time to see if they change. The goal is to find out if it's safe to avoid immediate surgery.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
Hear when a new BRAF V600E trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.